AADI - Cancer Player Aadi Bioscience Downgraded: Analyst Highlights 'Worse Than Expected' Response Rates | Benzinga
Friday, Aadi Bioscience Inc (NASDAQ: AADI) released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations.
H.C. Wainwright notes that nab-sirolimus achieved a 26% and 11% investigator-assessed objective response rate (ORR) in tumors-harboring TSC1 and TSC2 inactivating alterations, respectively; this is significantly lower than what was observed in the exploratory analysis of data from the AMPECT trial, wherein nine of 14 (64%) ...